APA (7th ed.) Citation

Lyu, Y. S., Lee, H., Kim, K., Hong, S., & Park, C. (2025). Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes. Cardiovascular Diabetology, 24(1), 1. https://doi.org/10.1186/s12933-025-02917-z

Chicago Style (17th ed.) Citation

Lyu, Young Sang, Hansol Lee, Kyung-Soo Kim, Sangmo Hong, and Cheol-Young Park. "Weight-independent Amelioration of Adipokine Profile by Enavogliflozin, a Selective SGLT2 Inhibitor, in Patients with Type 2 Diabetes." Cardiovascular Diabetology 24, no. 1 (2025): 1. https://doi.org/10.1186/s12933-025-02917-z.

MLA (9th ed.) Citation

Lyu, Young Sang, et al. "Weight-independent Amelioration of Adipokine Profile by Enavogliflozin, a Selective SGLT2 Inhibitor, in Patients with Type 2 Diabetes." Cardiovascular Diabetology, vol. 24, no. 1, 2025, p. 1, https://doi.org/10.1186/s12933-025-02917-z.